{"id":9834,"date":"2024-09-28T15:40:58","date_gmt":"2024-09-28T08:40:58","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=9834"},"modified":"2024-09-28T15:40:58","modified_gmt":"2024-09-28T08:40:58","slug":"concord-medical-reports-financial-results-for-the-first-half-of-2024","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=9834","title":{"rendered":"Concord Medical Reports Financial Results for the First Half of 2024"},"content":{"rendered":"

BEIJING<\/span><\/span>, Sept. 27, 2024<\/span><\/span> \/PRNewswire\/ — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China<\/span>, today announced its unaudited consolidated financial results for the six months ended June 30, 2024<\/span>[1].<\/p>\n

2024 First Half Highlights<\/p>\n

Total net revenues were RMB218.8 million<\/span> (US$30.1 million<\/span>) in the first half of 2024, representing a 23.1% decrease from total net revenues of RMB284.5 million<\/span> in the same period last year. Total net revenues included the net revenues from the hospital business of RMB137.8 million<\/span> (US$19.0 million<\/span>) and the net revenues from the network business of RMB81.0 million<\/span> (US$11.1 million<\/span>). Gross loss was RMB41.6 million<\/span> (US$5.7 million<\/span>) in the first half of 2024, compared to the gross loss of RMB37.4 million<\/span> in the first half of 2023. The gross loss margin was 19.0% for the first half of 2024, compared to 13.2% for the same period last year. Net loss attributable to ordinary shareholders in the first half of 2024 was RMB172.3 million<\/span> (US$23.7 million<\/span>), compared to RMB91.0 million<\/span> in the same period last year. Basic and diluted loss per share for Class A and Class B ordinary shares in the first half of 2024 were both RMB1.31<\/span> (US$0.18)<\/span>, compared to RMB0.69<\/span> in the same period last year. Non-GAAP[2] net loss in the first half of 2024 was RMB328.7 million<\/span> (US$45.2 million<\/span>), compared to non-GAAP net loss of RMB210.3 million<\/span> in the same period last year. Non-GAAP basic and diluted loss per share for Class A and Class B ordinary shares in the first half of 2024 were both RMB1.31<\/span> (US$0.18)<\/span>, compared to RMB0.69<\/span> in the same period last year. Adjusted EBITDA[3] (non-GAAP) was negative RMB148.0 million<\/span> (US$20.4 million<\/span>) in the first half of 2024, compared to negative RMB148.4 million<\/span> in the same period last year. <\/p>\n

\u00a0<\/p>\n

\n

[1] This announcement contains translations of certain\u00a0RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations of RMB into U.S. dollars are made at a rate of RMB7.2672 to US$1.00, the noon buying rate in New York City for cable transfers payable in RMB, as certified for customs purposes by the Federal Reserve Bank of New York on June 28, 2024.<\/span><\/p>\n

[2] Non-GAAP net loss and non-GAAP basic and diluted loss per share for Class A and Class B ordinary shares are defined as their most directly comparable GAAP measures excluding the impact of share-based compensation expenses.<\/span><\/p>\n

[3] Adjusted EBITDA is defined as net income\/(loss) plus interest expenses, net, income tax expenses, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment.<\/span><\/p>\n<\/div>\n

Dr. Jianyu Yang<\/span>, Chairman and Chief Executive Officer of Concord Medical, commented, “In the past few years, Concord Medical has been actively building a solid foundation for its business development, as well as looking to the future by profoundly enhancing its expertise in oncology care and strengthening the competitiveness of its international diagnosis and treatment services. Concurrently, Concord Medical has been continually exploring the untapped potential of its network business, striving for growth and expansion.<\/p>\n

We are delighted to announce that, Guangzhou Concord Cancer Center (“Guangzhou Hospital”), a PRC subsidiary of our Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license for its proton equipment, as announced by the National Health Commission of the PRC on September 14, 2024<\/span>. Proton therapy services stand as a pivotal segment within Concord Medical’s hospital business, anticipated to deliver a significant boost to our revenue base upon its successful implementation. This endeavor will concurrently elevate Guangzhou Hospital’s profile and reputation. Looking ahead, we maintain a positive outlook on the growth potential of this sector, expecting continued development and expansion through 2025 and beyond.”<\/p>\n

2024 First Half Financial Results<\/p>\n

Net Revenues<\/p>\n

Hospital Business<\/p>\n

Net revenues from the hospital business were RMB137.8 million<\/span> (US$19.0 million<\/span>) in the first half of 2024, representing a 13.2% decrease from net revenues of RMB158.7 million<\/span> in the first half of 2023, mainly because (1) we downsized certain of our hospital business with lower profit margin, and (2) as we concentrated the resources in preparing our proton therapy business, the revenue from the medical institutions fluctuated in the short term.<\/p>\n

Network Business<\/p>\n

Net revenues from the network business were RMB81.0 million<\/span> (US$11.1 million<\/span>), representing a 35.6% decrease from net revenues of RMB125.8 million<\/span> in the first half of 2023, mainly because of the decreased demand for medical equipment, software and the relevant management and technical support services by our customers in current economic environment.<\/p>\n

Cost of Revenues<\/p>\n

Hospital Business<\/p>\n

Cost of revenues of the hospital business in the first half of 2024 was RMB174.0 million<\/span> (US$23.9 million<\/span>), representing a 14.9% decrease from cost of revenues of RMB204.4 million<\/span> in the first half of 2023, mainly because of (1) our overall efforts to improve operation efficiency and reduce costs, especially for staff costs, and (2) the decrease of consumables and maintenance cost, lease cost and staff cost along with the fluctuation in hospital business.<\/p>\n

Network Business<\/p>\n

Cost of revenues of the network business was RMB86.4 million<\/span> (US$11.9 million<\/span>), representing a 26.4% decrease from RMB117.5 million<\/span> in the first half of 2023, generally in line with the decrease in the business scale and revenue generated from sales and installation of medical equipment and software, management and technical support services.<\/p>\n

Gross Loss and Gross Loss Margin<\/p>\n

Hospital Business<\/p>\n

Gross loss from the hospital business was RMB36.2 million<\/span> (US$4.9 million<\/span>) in the first half of 2024, compared to RMB45.7 million<\/span> in the same period last year. The gross loss margin of the hospital business for the first half of 2024 was 26.3%, compared to the gross loss margin of 28.8% for the same period last year. The improvement in gross loss margin of the hospital business was primarily because of our overall efforts to improve operation efficiency and reduce costs.<\/p>\n

Network Business<\/p>\n

Gross loss from the network business was RMB5.4 million<\/span> (US$0.8 million<\/span>), compared to the gross profit of RMB8.3 million<\/span> in the first half of 2023. The gross loss margin of the network business for the first half of 2024 was 6.7%, relatively stable compared to the gross profit margin of 6.6% for the same period last year.<\/p>\n

Operating Expenses <\/p>\n

Selling expenses were RMB25.0 million<\/span> (US$3.4 million<\/span>) in the first half of 2024, compared to RMB26.4 million<\/span> in the first half of 2023. Selling expenses as a percentage of net revenues was 11.4% in the first half of 2024, compared to 9.3% in the first half of 2023.<\/p>\n

General and administrative expenses were RMB131.2 million<\/span> (US$18.1 million<\/span>) in the first half of 2024, of which employee benefit expenses were RMB62.4 million<\/span> (US$8.6 million<\/span>). In the same period of last year, general and administrative expenses were RMB150.2 million<\/span>. The decrease was mainly attributable to the decrease in staff cost and our overall efforts to improve operation efficiency. General and administrative expenses as a percentage of net revenues was 59.9% in the first half of 2024, compared to 52.8% in the first half of 2023.<\/p>\n

Capital Expenditures<\/p>\n

Comparing to RMB46.5 million<\/span> in the first half of 2023, capital expenditures were RMB168.4 million<\/span> (US$23.2 million<\/span>) in the first half of 2024, mainly due to the increase in deposit for non-current assets and construction fees for our hospital business.<\/p>\n

Accounts Receivable<\/p>\n

As of June 30, 2024<\/span>, accounts receivable were RMB78.2 million<\/span> (US$10.8 million<\/span>), representing a 6.4% increase from accounts receivable of RMB73.5 million<\/span> as of December 31, 2023<\/span>. The average period of sales outstanding for accounts receivable (also known as days sales outstanding) was 171 days in the first half of 2024.<\/p>\n

Bank Loans and Other Borrowings<\/p>\n

As of June 30, 2024<\/span>, the Company had bank loans and other borrowings totaling RMB3.4 billion<\/span> (US$463.6 million<\/span>).<\/p>\n

About Non-GAAP Financial Measures<\/p>\n

To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles (“GAAP”), Concord Medical uses certain non-GAAP measures. The Company presents certain of its financial information that is adjusted from results based on GAAP to exclude the impact of share-based compensation expenses, such as non-GAAP net loss and non-GAAP basic and diluted loss per share for Class A and Class B ordinary shares. The Company believes excluding share-based compensation expenses from its GAAP financial measures is useful for its management and investors to assess and analyze the Company’s core operating results, as such expense is not directly attributable to the underlying performance of the Company’s business operations and do not impact its current cash earnings. Concord Medical also believes these non-GAAP measures excluding share-based compensation expenses are important in helping investors to understand the Company’s current financial performance and future prospects and to compare business trends among different reporting periods on a consistent basis. In addition, Concord Medical also presents the non-GAAP measure of adjusted EBITDA, which is defined in this announcement as net loss plus interest expenses, net, income tax expenses, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment. Furthermore, adjusted EBITDA eliminates the impact of items that the Company does not consider to be indicative of the performance of the network business and hospital business. The Company believes investors will similarly use adjusted EBITDA as one of the key metrics to evaluate its financial performance and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be considered a substitute for or superior to GAAP results or as being comparable to results reported or forecasted by other companies. The non-GAAP measures have been reconciled to GAAP measures in the attached financial information.<\/p>\n

About Concord Medical<\/p>\n

Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China<\/span>. For more information, please see http:\/\/ir.ccm.cn<\/a>.<\/p>\n

Safe Harbor Statement<\/p>\n

This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company’s control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.<\/p>\n

\n

Concord Medical Services Holdings Co., Ltd.<\/span><\/p>\n

<\/p>\n

Consolidated Balance Sheets
(in thousands)<\/span><\/p>\n

December 31,<\/span><\/p>\n

2023<\/span><\/p>\n

<\/p>\n

June 30, 2024<\/span><\/p>\n

RMB<\/span><\/p>\n

<\/p>\n

RMB<\/span><\/p>\n

<\/p>\n

US$<\/span><\/p>\n

(Audited)<\/span><\/p>\n

<\/p>\n

(Unaudited)<\/span><\/p>\n

<\/p>\n

(Unaudited)<\/span><\/p>\n

<\/p>\n

ASSETS<\/span><\/p>\n

Current assets<\/span><\/p>\n

Cash and cash equivalents<\/span><\/p>\n

58,139<\/span><\/p>\n

<\/p>\n

115,667<\/span><\/p>\n

<\/p>\n

15,916<\/span><\/p>\n

<\/p>\n

Short-term investment<\/span><\/p>\n

–<\/span><\/p>\n

<\/p>\n

211,238<\/span><\/p>\n

<\/p>\n

29,067<\/span><\/p>\n

<\/p>\n

Restricted cash, current portion<\/span><\/p>\n

32,280<\/span><\/p>\n

<\/p>\n

10,116<\/span><\/p>\n

<\/p>\n

1,392<\/span><\/p>\n

<\/p>\n

Accounts receivable, net<\/span><\/p>\n

73,496<\/span><\/p>\n

<\/p>\n

78,222<\/span><\/p>\n

<\/p>\n

10,764<\/span><\/p>\n

<\/p>\n

Prepayments and other current assets, net<\/span><\/p>\n

412,946<\/span><\/p>\n

<\/p>\n

574,330<\/span><\/p>\n

<\/p>\n

79,030<\/span><\/p>\n

<\/p>\n

Inventories<\/span><\/p>\n

40,347<\/span><\/p>\n

<\/p>\n

39,832<\/span><\/p>\n

<\/p>\n

5,481<\/span><\/p>\n

<\/p>\n

Total current assets<\/span><\/p>\n

617,208<\/span><\/p>\n

<\/p>\n

1,029,405<\/span><\/p>\n

<\/p>\n

141,650<\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

Non-current assets<\/span><\/p>\n

Property, plant and equipment, net<\/span><\/p>\n

3,546,873<\/span><\/p>\n

<\/p>\n

3,555,860<\/span><\/p>\n

<\/p>\n

489,303<\/span><\/p>\n

<\/p>\n

Right-of-use assets, net<\/span><\/p>\n

580,365<\/span><\/p>\n

<\/p>\n

538,514<\/span><\/p>\n

<\/p>\n

74,102<\/span><\/p>\n

<\/p>\n

Goodwill<\/span><\/p>\n

575,427<\/span><\/p>\n

<\/p>\n

572,216<\/span><\/p>\n

<\/p>\n

78,740<\/span><\/p>\n

<\/p>\n

Intangible assets, net<\/span><\/p>\n

323,287<\/span><\/p>\n

<\/p>\n

300,569<\/span><\/p>\n

<\/p>\n

41,360<\/span><\/p>\n

<\/p>\n

Deposits for non-current assets <\/span><\/p>\n

4,646<\/span><\/p>\n

<\/p>\n

139,085<\/span><\/p>\n

<\/p>\n

19,139<\/span><\/p>\n

<\/p>\n

Long-term investments<\/span><\/p>\n

394,711<\/span><\/p>\n

<\/p>\n

480,873<\/span><\/p>\n

<\/p>\n

66,170<\/span><\/p>\n

<\/p>\n

Other non-current assets<\/span><\/p>\n

11,426<\/span><\/p>\n

<\/p>\n

6,171<\/span><\/p>\n

<\/p>\n

849<\/span><\/p>\n

<\/p>\n

Total non-current assets<\/span><\/p>\n

5,436,735<\/span><\/p>\n

<\/p>\n

5,593,288<\/span><\/p>\n

<\/p>\n

769,663<\/span><\/p>\n

Total assets<\/span><\/p>\n

6,053,943<\/span><\/p>\n

<\/p>\n

6,622,693<\/span><\/p>\n

<\/p>\n

911,313<\/span><\/p>\n

<\/p>\n

\u00a0<\/p>\n

\u00a0<\/span><\/p>\n

LIABILITIES AND EQUITY<\/span><\/p>\n

Current liabilities<\/span><\/p>\n

Accounts payable<\/span><\/p>\n

129,236<\/span><\/p>\n

<\/p>\n

127,334<\/span><\/p>\n

<\/p>\n

17,522<\/span><\/p>\n

<\/p>\n

Accrued expenses and other liabilities<\/span><\/p>\n

731,793<\/span><\/p>\n

<\/p>\n

740,827<\/span><\/p>\n

<\/p>\n

101,940<\/span><\/p>\n

<\/p>\n

Income tax payable<\/span><\/p>\n

1,522<\/span><\/p>\n

<\/p>\n

1,581<\/span><\/p>\n

<\/p>\n

218<\/span><\/p>\n

<\/p>\n

Operating lease liabilities, current<\/span><\/p>\n

46,492<\/span><\/p>\n

<\/p>\n

35,700<\/span><\/p>\n

<\/p>\n

4,912<\/span><\/p>\n

<\/p>\n

Short-term bank and other borrowings<\/span><\/p>\n

319,625<\/span><\/p>\n

<\/p>\n

363,446<\/span><\/p>\n

<\/p>\n

50,012<\/span><\/p>\n

<\/p>\n

Long-term bank and other borrowings, current portion<\/span><\/p>\n

722,563<\/span><\/p>\n

<\/p>\n

793,760<\/span><\/p>\n

<\/p>\n

109,225<\/span><\/p>\n

<\/p>\n

Derivative liability<\/span><\/p>\n

163<\/span><\/p>\n

<\/p>\n

109,632<\/span><\/p>\n

<\/p>\n

15,086<\/span><\/p>\n

<\/p>\n

Total current liabilities<\/span><\/p>\n

1,951,394<\/span><\/p>\n

<\/p>\n

2,172,280<\/span><\/p>\n

<\/p>\n

298,915<\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

Non-current liabilities<\/span><\/p>\n

Long-term bank and other borrowings, non-current portion<\/span><\/p>\n

1,994,014<\/span><\/p>\n

<\/p>\n

2,211,862<\/span><\/p>\n

<\/p>\n

304,362<\/span><\/p>\n

<\/p>\n

Deferred tax liabilities<\/span><\/p>\n

99,538<\/span><\/p>\n

<\/p>\n

92,807<\/span><\/p>\n

<\/p>\n

12,771<\/span><\/p>\n

<\/p>\n

Operating lease liabilities, non-current<\/span><\/p>\n

193,007<\/span><\/p>\n

<\/p>\n

159,461<\/span><\/p>\n

<\/p>\n

21,943<\/span><\/p>\n

<\/p>\n

Other long-term liabilities<\/span><\/p>\n

69,003<\/span><\/p>\n

<\/p>\n

65,397<\/span><\/p>\n

<\/p>\n

9,000<\/span><\/p>\n

<\/p>\n

Total non-current liabilities<\/span><\/p>\n

2,355,562<\/span><\/p>\n

<\/p>\n

2,529,527<\/span><\/p>\n

<\/p>\n

348,076<\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

Total liabilities<\/span><\/p>\n

\u00a0<\/p>\n

4,306,956<\/span><\/p>\n

<\/p>\n

\u00a0<\/p>\n

4,701,807<\/span><\/p>\n

<\/p>\n

\u00a0<\/p>\n

646,991<\/span><\/p>\n

<\/p>\n

EQUITY<\/span><\/p>\n

Class A ordinary shares<\/span><\/p>\n

68<\/span><\/p>\n

<\/p>\n

68<\/span><\/p>\n

<\/p>\n

9<\/span><\/p>\n

<\/p>\n

Class B ordinary shares<\/span><\/p>\n

37<\/span><\/p>\n

<\/p>\n

37<\/span><\/p>\n

<\/p>\n

5<\/span><\/p>\n

<\/p>\n

Treasury stock<\/span><\/p>\n

(7)<\/span><\/p>\n

<\/p>\n

(7)<\/span><\/p>\n

<\/p>\n

(1)<\/span><\/p>\n

<\/p>\n

Additional paid-in capital<\/span><\/p>\n

2,007,965<\/span><\/p>\n

<\/p>\n

2,169,695<\/span><\/p>\n

<\/p>\n

298,560<\/span><\/p>\n

<\/p>\n

Accumulated other comprehensive loss<\/span><\/p>\n

(65,419)<\/span><\/p>\n

<\/p>\n

(71,694)<\/span><\/p>\n

<\/p>\n

(9,865)<\/span><\/p>\n

<\/p>\n

Accumulated deficit<\/span><\/p>\n

(4,064,589)<\/span><\/p>\n

<\/p>\n

(4,236,847)<\/span><\/p>\n

<\/p>\n

(583,010)<\/span><\/p>\n

<\/p>\n

Total Concord Medical Services Holdings Limited shareholders’ deficit<\/span><\/p>\n

(2,121,945)<\/span><\/p>\n

<\/p>\n

(2,138,748)<\/span><\/p>\n

<\/p>\n

(294,302)<\/span><\/p>\n

<\/p>\n

Noncontrolling interests<\/span><\/p>\n

3,868,932<\/span><\/p>\n

<\/p>\n

4,059,634<\/span><\/p>\n

<\/p>\n

558,624<\/span><\/p>\n

Total equity<\/span><\/p>\n

1,746,987<\/span><\/p>\n

<\/p>\n

1,920,886<\/span><\/p>\n

<\/p>\n

264,322<\/span><\/p>\n

Total liabilities and equity<\/span><\/p>\n

6,053,943<\/span><\/p>\n

<\/p>\n

6,622,693<\/span><\/p>\n

<\/p>\n

911,313<\/span><\/p>\n

<\/p><\/div>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\n

Concord Medical Services Holdings Co., Ltd.<\/span><\/p>\n

Consolidated Profit & Loss<\/span><\/p>\n

(in thousands, except for number of shares and per share data)<\/span><\/p>\n

June 30,
2023<\/span><\/p>\n

<\/p>\n

June 30, 2024<\/span><\/p>\n

<\/p>\n

RMB<\/span><\/p>\n

<\/p>\n

RMB<\/span><\/p>\n

<\/p>\n

US$<\/span><\/p>\n

<\/p>\n

(Unaudited)<\/span><\/p>\n

<\/p>\n

(Unaudited)<\/span><\/p>\n

<\/p>\n

(Unaudited)<\/span><\/p>\n

Revenues, net of business tax, value-added tax and related
surcharges<\/span><\/p>\n

<\/p>\n

Hospital<\/span><\/p>\n

158,707<\/span><\/p>\n

<\/p>\n

137,772<\/span><\/p>\n

<\/p>\n

18,958<\/span><\/p>\n

Network<\/span><\/p>\n

125,806<\/span><\/p>\n

<\/p>\n

81,038<\/span><\/p>\n

<\/p>\n

11,151<\/span><\/p>\n

Total net revenues<\/span><\/p>\n

284,513<\/span><\/p>\n

<\/p>\n

218,810<\/span><\/p>\n

<\/p>\n

30,109<\/span><\/p>\n

Cost of revenues:<\/span><\/p>\n

<\/p>\n

Hospital<\/span><\/p>\n

(204,433)<\/span><\/p>\n

<\/p>\n

(173,963)<\/span><\/p>\n

<\/p>\n

(23,938)<\/span><\/p>\n

Network<\/span><\/p>\n

(117,503)<\/span><\/p>\n

<\/p>\n

(86,443)<\/span><\/p>\n

<\/p>\n

(11,895)<\/span><\/p>\n

Total cost of revenues<\/span><\/p>\n

(321,936)<\/span><\/p>\n

<\/p>\n

(260,406)<\/span><\/p>\n

<\/p>\n

(35,833)<\/span><\/p>\n

Gross loss<\/span><\/p>\n

(37,423)<\/span><\/p>\n

<\/p>\n

(41,596)<\/span><\/p>\n

<\/p>\n

(5,724)<\/span><\/p>\n

Operating expenses:<\/span><\/p>\n

<\/p>\n

Selling expenses<\/span><\/p>\n

(26,362)<\/span><\/p>\n

<\/p>\n

(24,975)<\/span><\/p>\n

<\/p>\n

(3,437)<\/span><\/p>\n

General and administrative expenses<\/span><\/p>\n

(150,240)<\/span><\/p>\n

<\/p>\n

(131,173)<\/span><\/p>\n

<\/p>\n

(18,050)<\/span><\/p>\n

Operating loss<\/span><\/p>\n

(214,025)<\/span><\/p>\n

<\/p>\n

(197,744)<\/span><\/p>\n

<\/p>\n

(27,211)<\/span><\/p>\n

Interest expense<\/span><\/p>\n

(84,374)<\/span><\/p>\n

<\/p>\n

(68,668)<\/span><\/p>\n

<\/p>\n

(9,449)<\/span><\/p>\n

Foreign exchange loss, net<\/span><\/p>\n

(2,444)<\/span><\/p>\n

<\/p>\n

(30,269)<\/span><\/p>\n

<\/p>\n

(4,165)<\/span><\/p>\n

Gain on disposal of long-lived equipment<\/span><\/p>\n

62<\/span><\/p>\n

<\/p>\n

–<\/span><\/p>\n

<\/p>\n

–<\/span><\/p>\n

Interest income<\/span><\/p>\n

5,800<\/span><\/p>\n

<\/p>\n

5,990<\/span><\/p>\n

<\/p>\n

824<\/span><\/p>\n

Change in fair value of derivative liability<\/span><\/p>\n

–<\/span><\/p>\n

<\/p>\n

(108,777)<\/span><\/p>\n

<\/p>\n

(14,968)<\/span><\/p>\n

Income from equity method investments<\/span><\/p>\n

10,099<\/span><\/p>\n

<\/p>\n

6,070<\/span><\/p>\n

<\/p>\n

835<\/span><\/p>\n

Gain on disposal of subsidiaries<\/span><\/p>\n

–<\/span><\/p>\n

<\/p>\n

47,997<\/span><\/p>\n

<\/p>\n

6,605<\/span><\/p>\n

Other income, net<\/span><\/p>\n

13,623<\/span><\/p>\n

<\/p>\n

1,388<\/span><\/p>\n

<\/p>\n

191<\/span><\/p>\n

Gain on disposal of equity method investment<\/span><\/p>\n

37,498<\/span><\/p>\n

<\/p>\n

–<\/span><\/p>\n

<\/p>\n

–<\/span><\/p>\n

Changes in fair value of short-term investments<\/span><\/p>\n

–<\/span><\/p>\n

<\/p>\n

6,631<\/span><\/p>\n

<\/p>\n

912<\/span><\/p>\n

Loss before income tax<\/span><\/p>\n

(233,761)<\/span><\/p>\n

<\/p>\n

(337,382)<\/span><\/p>\n

<\/p>\n

(46,426)<\/span><\/p>\n

Income tax expenses<\/span><\/p>\n

23,417<\/span><\/p>\n

<\/p>\n

8,674<\/span><\/p>\n

<\/p>\n

1,194<\/span><\/p>\n

Net loss<\/span><\/p>\n

(210,344)<\/span><\/p>\n

<\/p>\n

(328,708)<\/span><\/p>\n

<\/p>\n

(45,232)<\/span><\/p>\n

Net loss attributable to noncontrolling interests<\/span><\/p>\n

(119,359)<\/span><\/p>\n

<\/p>\n

(156,450)<\/span><\/p>\n

<\/p>\n

(21,528)<\/span><\/p>\n

Net loss attributable to Concord Medical Services Holdings
Limited<\/span><\/p>\n

(90,985)<\/span><\/p>\n

<\/p>\n

(172,258)<\/span><\/p>\n

<\/p>\n

(23,704)<\/span><\/p>\n

Loss per share for Class A and Class B ordinary shares<\/span><\/p>\n

<\/p>\n

Basic<\/span><\/p>\n

(0.69)<\/span><\/p>\n

<\/p>\n

(1.31)<\/span><\/p>\n

<\/p>\n

(0.18)<\/span><\/p>\n

Diluted<\/span><\/p>\n

(0.69)<\/span><\/p>\n

<\/p>\n

(1.31)<\/span><\/p>\n

<\/p>\n

(0.18)<\/span><\/p>\n

Weighted average number of class A and class B ordinary shares
outstanding:<\/span><\/p>\n

<\/p>\n

Basic<\/span><\/p>\n

131,053,858<\/span><\/p>\n

<\/p>\n

131,053,858<\/span><\/p>\n

<\/p>\n

131,053,858<\/span><\/p>\n

Diluted<\/span><\/p>\n

131,053,858<\/span><\/p>\n

<\/p>\n

131,053,858<\/span><\/p>\n

<\/p>\n

131,053,858<\/span><\/p>\n

Other comprehensive loss, net of tax of nil<\/span><\/p>\n

<\/p>\n

Foreign currency translation, net of tax of nil<\/span><\/p>\n

(17,371)<\/span><\/p>\n

<\/p>\n

(6,273)<\/span><\/p>\n

<\/p>\n

(863)<\/span><\/p>\n

Total other comprehensive loss, net of tax<\/span><\/p>\n

(17,371)<\/span><\/p>\n

<\/p>\n

(6,273)<\/span><\/p>\n

<\/p>\n

(863)<\/span><\/p>\n

Comprehensive loss<\/span><\/p>\n

(227,715)<\/span><\/p>\n

<\/p>\n

(334,981)<\/span><\/p>\n

<\/p>\n

(46,095)<\/span><\/p>\n

Comprehensive loss attributable to noncontrolling interests<\/span><\/p>\n

(119,359)<\/span><\/p>\n

<\/p>\n

(156,450)<\/span><\/p>\n

<\/p>\n

(21,528)<\/span><\/p>\n

Comprehensive loss attributable to Concord Medical Services
Holdings Limited’s shareholders<\/span><\/p>\n

(108,356)<\/span><\/p>\n

<\/p>\n

(178,531)<\/span><\/p>\n

<\/p>\n

(24,567)<\/span><\/p>\n<\/div>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\n

Reconciliations\u00a0of non-GAAP results of operations measures to the
nearest comparable GAAP measures<\/span><\/p>\n

(in\u00a0RMB\u00a0thousands, except per share data unaudited)<\/span><\/p>\n

<\/p>\n

For the six months ended<\/span><\/p>\n

<\/p>\n

For the six months ended<\/span><\/p>\n

June 30, 2023<\/span><\/p>\n

<\/p>\n

June 30, 2024<\/span><\/p>\n

Non-<\/span><\/p>\n

<\/p>\n

Non-<\/span><\/p>\n

GAAP<\/span><\/p>\n

<\/p>\n

GAAP<\/span><\/p>\n

<\/p>\n

GAAP<\/span><\/p>\n

<\/p>\n

GAAP<\/span><\/p>\n

Measure<\/span><\/p>\n

<\/p>\n

Adjustment<\/span><\/p>\n

<\/p>\n

Measure<\/span><\/p>\n

<\/p>\n

Measure<\/span><\/p>\n

<\/p>\n

Adjustment<\/span><\/p>\n

<\/p>\n

Measure<\/span><\/p>\n

Operating loss<\/span><\/p>\n

<\/p>\n

(214,025)<\/span><\/p>\n

<\/p>\n

–<\/span><\/p>\n

<\/p>\n

(214,025)<\/span><\/p>\n

<\/p>\n

(197,744)<\/span><\/p>\n

<\/p>\n

–<\/span><\/p>\n

<\/p>\n

(197,744)<\/span><\/p>\n

Net loss<\/span><\/p>\n

<\/p>\n

(210,344)<\/span><\/p>\n

<\/p>\n

–<\/span><\/p>\n

<\/p>\n

(210,344)<\/span><\/p>\n

<\/p>\n

(328,708)<\/span><\/p>\n

<\/p>\n

–<\/span><\/p>\n

<\/p>\n

(328,708)<\/span><\/p>\n

Basic loss per share for
\u00a0 Class A and<\/span><\/p>\n

Class B ordinary
\u00a0 shares<\/span><\/p>\n

<\/p>\n

(0.69)<\/span><\/p>\n

<\/p>\n

–<\/span><\/p>\n

<\/p>\n

(0.69)<\/span><\/p>\n

<\/p>\n

(1.31)<\/span><\/p>\n

<\/p>\n

–<\/span><\/p>\n

<\/p>\n

(1.31)<\/span><\/p>\n

Diluted loss per share
\u00a0 for Class A and<\/span><\/p>\n

Class B ordinary
\u00a0 shares<\/span><\/p>\n

<\/p>\n

(0.69)<\/span><\/p>\n

<\/p>\n

–<\/span><\/p>\n

<\/p>\n

(0.69)<\/span><\/p>\n

<\/p>\n

(1.31)<\/span><\/p>\n

<\/p>\n

–<\/span><\/p>\n

<\/p>\n

(1.31)<\/span><\/p>\n

<\/p><\/div>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\n

Reconciliation from net income to adjusted EBITDA(*) (in\u00a0RMB\u00a0
thousands, unaudited)<\/span><\/p>\n

For the six months ended<\/span><\/p>\n

<\/p>\n

For the six months ended<\/span><\/p>\n

<\/p>\n

June 30, 2023<\/span><\/p>\n

<\/p>\n

June 30, 2024<\/span><\/p>\n

Net loss<\/span><\/p>\n

(210,344)<\/span><\/p>\n

<\/p>\n

(328,708)<\/span><\/p>\n

Interest expenses, net<\/span><\/p>\n

78,574<\/span><\/p>\n

<\/p>\n

62,678<\/span><\/p>\n

Income tax expenses<\/span><\/p>\n

(23,417)<\/span><\/p>\n

<\/p>\n

(8,674)<\/span><\/p>\n

Depreciation and amortization<\/span><\/p>\n

55,537<\/span><\/p>\n

<\/p>\n

43,654<\/span><\/p>\n

Share-based compensation<\/span><\/p>\n

–<\/span><\/p>\n

<\/p>\n

–<\/span><\/p>\n

Other adjustments<\/span><\/p>\n

(48,739)<\/span><\/p>\n

<\/p>\n

83,030<\/span><\/p>\n

Adjusted EBITDA<\/span><\/p>\n

(148,389)<\/span><\/p>\n

<\/p>\n

(148,020)<\/span><\/p>\n

EBITDA margin<\/span><\/p>\n

-52\u00a0%<\/span><\/p>\n

<\/p>\n

-68\u00a0%<\/span><\/p>\n

<\/p>\n

(*) Definition of adjusted EBITDA: Adjusted EBITDA is defined as net loss plus interest expenses, net, income tax expenses,
depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign
exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair
value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment.\u00a0<\/span><\/p>\n<\/div>\n

\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

BEIJING<\/span><\/span>, Sept. 27, 2024<\/span><\/span> \/PRNewswire\/ — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China<\/span>, today announced its unaudited consolidated financial results for the six months ended June 30, 2024<\/span>[1].<\/p>\n

2024 First Half Highlights<\/p>\n

Total net revenues were RMB218.8 million<\/span> (US$30.1 million<\/span>) in the first half of 2024, representing a 23.1% decrease from total net revenues of RMB284.5 million<\/span> in the same period last year. Total net revenues included the net revenues from the hospital business of RMB137.8 million<\/span> (US$19.0 million<\/span>) and the net revenues from the network business of RMB81.0 million<\/span> (US$11.1 million<\/span>). Gross loss was RMB41.6 million<\/span> (US$5.7 million<\/span>) in the first half of 2024, compared to the gross loss of RMB37.4 million<\/span> in the first half of 2023. The gross loss margin was 19.0% for the first half of 2024, compared to 13.2% for the same period last year. Net loss attributable to ordinary shareholders in the first half of 2024 was RMB172.3 million<\/span> (US$23.7 million<\/span>), compared to RMB91.0 million<\/span> in the same period last year. Basic and diluted loss per share for Class A and Class B ordinary shares in the first half of 2024 were both RMB1.31<\/span> (US$0.18)<\/span>, compared to RMB0.69<\/span> in the same period last year. Non-GAAP[2] net loss in the first half of 2024 was RMB328.7 million<\/span> (US$45.2 million<\/span>), compared to non-GAAP net loss of RMB210.3 million<\/span> in the same period last year. Non-GAAP basic and diluted loss per share for Class A and Class B ordinary shares in the first half of 2024 were both RMB1.31<\/span> (US$0.18)<\/span>, compared to RMB0.69<\/span> in the same period last year. Adjusted EBITDA[3] (non-GAAP) was negative RMB148.0 million<\/span> (US$20.4 million<\/span>) in the first half of 2024, compared to negative RMB148.4 million<\/span> in the same period last year. <\/p>\n

\u00a0<\/p>\n

\n

[1] This announcement contains translations of certain\u00a0RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations of RMB into U.S. dollars are made at a rate of RMB7.2672 to US$1.00, the noon buying rate in New York City for cable transfers payable in RMB, as certified for customs purposes by the Federal Reserve Bank of New York on June 28, 2024.<\/span><\/p>\n

[2] Non-GAAP net loss and non-GAAP basic and diluted loss per share for Class A and Class B ordinary shares are defined as their most directly comparable GAAP measures excluding the impact of share-based compensation expenses.<\/span><\/p>\n

[3] Adjusted EBITDA is defined as net income\/(loss) plus interest expenses, net, income tax expenses, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment.<\/span><\/p>\n<\/div>\n

Dr. Jianyu Yang<\/span>, Chairman and Chief Executive Officer of Concord Medical, commented, “In the past few years, Concord Medical has been actively building a solid foundation for its business development, as well as looking to the future by profoundly enhancing its expertise in oncology care and strengthening the competitiveness of its international diagnosis and treatment services. Concurrently, Concord Medical has been continually exploring the untapped potential of its network business, striving for growth and expansion.<\/p>\n

We are delighted to announce that, Guangzhou Concord Cancer Center (“Guangzhou Hospital”), a PRC subsidiary of our Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license for its proton equipment, as announced by the National Health Commission of the PRC on September 14, 2024<\/span>. Proton therapy services stand as a pivotal segment within Concord Medical’s hospital business, anticipated to deliver a significant boost to our revenue base upon its successful implementation. This endeavor will concurrently elevate Guangzhou Hospital’s profile and reputation. Looking ahead, we maintain a positive outlook on the growth potential of this sector, expecting continued development and expansion through 2025 and beyond.”<\/p>\n

2024 First Half Financial Results<\/p>\n

Net Revenues<\/p>\n

Hospital Business<\/p>\n

Net revenues from the hospital business were RMB137.8 million<\/span> (US$19.0 million<\/span>) in the first half of 2024, representing a 13.2% decrease from net revenues of RMB158.7 million<\/span> in the first half of 2023, mainly because (1) we downsized certain of our hospital business with lower profit margin, and (2) as we concentrated the resources in preparing our proton therapy business, the revenue from the medical institutions fluctuated in the short term.<\/p>\n

Network Business<\/p>\n

Net revenues from the network business were RMB81.0 million<\/span> (US$11.1 million<\/span>), representing a 35.6% decrease from net revenues of RMB125.8 million<\/span> in the first half of 2023, mainly because of the decreased demand for medical equipment, software and the relevant management and technical support services by our customers in current economic environment.<\/p>\n

Cost of Revenues<\/p>\n

Hospital Business<\/p>\n

Cost of revenues of the hospital business in the first half of 2024 was RMB174.0 million<\/span> (US$23.9 million<\/span>), representing a 14.9% decrease from cost of revenues of RMB204.4 million<\/span> in the first half of 2023, mainly because of (1) our overall efforts to improve operation efficiency and reduce costs, especially for staff costs, and (2) the decrease of consumables and maintenance cost, lease cost and staff cost along with the fluctuation in hospital business.<\/p>\n

Network Business<\/p>\n

Cost of revenues of the network business was RMB86.4 million<\/span> (US$11.9 million<\/span>), representing a 26.4% decrease from RMB117.5 million<\/span> in the first half of 2023, generally in line with the decrease in the business scale and revenue generated from sales and installation of medical equipment and software, management and technical support services.<\/p>\n

Gross Loss and Gross Loss Margin<\/p>\n

Hospital Business<\/p>\n

Gross loss from the hospital business was RMB36.2 million<\/span> (US$4.9 million<\/span>) in the first half of 2024, compared to RMB45.7 million<\/span> in the same period last year. The gross loss margin of the hospital business for the first half of 2024 was 26.3%, compared to the gross loss margin of 28.8% for the same period last year. The improvement in gross loss margin of the hospital business was primarily because of our overall efforts to improve operation efficiency and reduce costs.<\/p>\n

Network Business<\/p>\n

Gross loss from the network business was RMB5.4 million<\/span> (US$0.8 million<\/span>), compared to the gross profit of RMB8.3 million<\/span> in the first half of 2023. The gross loss margin of the network business for the first half of 2024 was 6.7%, relatively stable compared to the gross profit margin of 6.6% for the same period last year.<\/p>\n

Operating Expenses <\/p>\n

Selling expenses were RMB25.0 million<\/span> (US$3.4 million<\/span>) in the first half of 2024, compared to RMB26.4 million<\/span> in the first half of 2023. Selling expenses as a percentage of net revenues was 11.4% in the first half of 2024, compared to 9.3% in the first half of 2023.<\/p>\n

General and administrative expenses were RMB131.2 million<\/span> (US$18.1 million<\/span>) in the first half of 2024, of which employee benefit expenses were RMB62.4 million<\/span> (US$8.6 million<\/span>). In the same period of last year, general and administrative expenses were RMB150.2 million<\/span>. The decrease was mainly attributable to the decrease in staff cost and our overall efforts to improve operation efficiency. General and administrative expenses as a percentage of net revenues was 59.9% in the first half of 2024, compared to 52.8% in the first half of 2023.<\/p>\n

Capital Expenditures<\/p>\n

Comparing to RMB46.5 million<\/span> in the first half of 2023, capital expenditures were RMB168.4 million<\/span> (US$23.2 million<\/span>) in the first half of 2024, mainly due to the increase in deposit for non-current assets and construction fees for our hospital business.<\/p>\n

Accounts Receivable<\/p>\n

As of June 30, 2024<\/span>, accounts receivable were RMB78.2 million<\/span> (US$10.8 million<\/span>), representing a 6.4% increase from accounts receivable of RMB73.5 million<\/span> as of December 31, 2023<\/span>. The average period of sales outstanding for accounts receivable (also known as days sales outstanding) was 171 days in the first half of 2024.<\/p>\n

Bank Loans and Other Borrowings<\/p>\n

As of June 30, 2024<\/span>, the Company had bank loans and other borrowings totaling RMB3.4 billion<\/span> (US$463.6 million<\/span>).<\/p>\n

About Non-GAAP Financial Measures<\/p>\n

To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles (“GAAP”), Concord Medical uses certain non-GAAP measures. The Company presents certain of its financial information that is adjusted from results based on GAAP to exclude the impact of share-based compensation expenses, such as non-GAAP net loss and non-GAAP basic and diluted loss per share for Class A and Class B ordinary shares. The Company believes excluding share-based compensation expenses from its GAAP financial measures is useful for its management and investors to assess and analyze the Company’s core operating results, as such expense is not directly attributable to the underlying performance of the Company’s business operations and do not impact its current cash earnings. Concord Medical also believes these non-GAAP measures excluding share-based compensation expenses are important in helping investors to understand the Company’s current financial performance and future prospects and to compare business trends among different reporting periods on a consistent basis. In addition, Concord Medical also presents the non-GAAP measure of adjusted EBITDA, which is defined in this announcement as net loss plus interest expenses, net, income tax expenses, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment. Furthermore, adjusted EBITDA eliminates the impact of items that the Company does not consider to be indicative of the performance of the network business and hospital business. The Company believes investors will similarly use adjusted EBITDA as one of the key metrics to evaluate its financial performance and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be considered a substitute for or superior to GAAP results or as being comparable to results reported or forecasted by other companies. The non-GAAP measures have been reconciled to GAAP measures in the attached financial information.<\/p>\n

About Concord Medical<\/p>\n

Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China<\/span>. For more information, please see http:\/\/ir.ccm.cn<\/a>.<\/p>\n

Safe Harbor Statement<\/p>\n

This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company’s control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.<\/p>\n

\n

Concord Medical Services Holdings Co., Ltd.<\/span><\/p>\n<\/p>\n

Consolidated Balance Sheets
(in thousands)<\/span><\/p>\n

December 31,<\/span><\/p>\n

2023<\/span><\/p>\n<\/p>\n

June 30, 2024<\/span><\/p>\n

RMB<\/span><\/p>\n<\/p>\n

RMB<\/span><\/p>\n<\/p>\n

US$<\/span><\/p>\n

(Audited)<\/span><\/p>\n<\/p>\n

(Unaudited)<\/span><\/p>\n<\/p>\n

(Unaudited)<\/span><\/p>\n<\/p>\n

ASSETS<\/span><\/p>\n

Current assets<\/span><\/p>\n

Cash and cash equivalents<\/span><\/p>\n

58,139<\/span><\/p>\n<\/p>\n

115,667<\/span><\/p>\n<\/p>\n

15,916<\/span><\/p>\n<\/p>\n

Short-term investment<\/span><\/p>\n

–<\/span><\/p>\n<\/p>\n

211,238<\/span><\/p>\n<\/p>\n

29,067<\/span><\/p>\n<\/p>\n

Restricted cash, current portion<\/span><\/p>\n

32,280<\/span><\/p>\n<\/p>\n

10,116<\/span><\/p>\n<\/p>\n

1,392<\/span><\/p>\n<\/p>\n

Accounts receivable, net<\/span><\/p>\n

73,496<\/span><\/p>\n<\/p>\n

78,222<\/span><\/p>\n<\/p>\n

10,764<\/span><\/p>\n<\/p>\n

Prepayments and other current assets, net<\/span><\/p>\n

412,946<\/span><\/p>\n<\/p>\n

574,330<\/span><\/p>\n<\/p>\n

79,030<\/span><\/p>\n<\/p>\n

Inventories<\/span><\/p>\n

40,347<\/span><\/p>\n<\/p>\n

39,832<\/span><\/p>\n<\/p>\n

5,481<\/span><\/p>\n<\/p>\n

Total current assets<\/span><\/p>\n

617,208<\/span><\/p>\n<\/p>\n

1,029,405<\/span><\/p>\n<\/p>\n

141,650<\/span><\/p>\n<\/p>\n

\u00a0<\/span><\/p>\n

Non-current assets<\/span><\/p>\n

Property, plant and equipment, net<\/span><\/p>\n

3,546,873<\/span><\/p>\n<\/p>\n

3,555,860<\/span><\/p>\n<\/p>\n

489,303<\/span><\/p>\n<\/p>\n

Right-of-use assets, net<\/span><\/p>\n

580,365<\/span><\/p>\n<\/p>\n

538,514<\/span><\/p>\n<\/p>\n

74,102<\/span><\/p>\n<\/p>\n

Goodwill<\/span><\/p>\n

575,427<\/span><\/p>\n<\/p>\n

572,216<\/span><\/p>\n<\/p>\n

78,740<\/span><\/p>\n<\/p>\n

Intangible assets, net<\/span><\/p>\n

323,287<\/span><\/p>\n<\/p>\n

300,569<\/span><\/p>\n<\/p>\n

41,360<\/span><\/p>\n<\/p>\n

Deposits for non-current assets <\/span><\/p>\n

4,646<\/span><\/p>\n<\/p>\n

139,085<\/span><\/p>\n<\/p>\n

19,139<\/span><\/p>\n<\/p>\n

Long-term investments<\/span><\/p>\n

394,711<\/span><\/p>\n<\/p>\n

480,873<\/span><\/p>\n<\/p>\n

66,170<\/span><\/p>\n<\/p>\n

Other non-current assets<\/span><\/p>\n

11,426<\/span><\/p>\n<\/p>\n

6,171<\/span><\/p>\n<\/p>\n

849<\/span><\/p>\n<\/p>\n

Total non-current assets<\/span><\/p>\n

5,436,735<\/span><\/p>\n<\/p>\n

5,593,288<\/span><\/p>\n<\/p>\n

769,663<\/span><\/p>\n

Total assets<\/span><\/p>\n

6,053,943<\/span><\/p>\n<\/p>\n

6,622,693<\/span><\/p>\n<\/p>\n

911,313<\/span><\/p>\n<\/p>\n

\u00a0<\/p>\n

\u00a0<\/span><\/p>\n

LIABILITIES AND EQUITY<\/span><\/p>\n

Current liabilities<\/span><\/p>\n

Accounts payable<\/span><\/p>\n

129,236<\/span><\/p>\n<\/p>\n

127,334<\/span><\/p>\n<\/p>\n

17,522<\/span><\/p>\n<\/p>\n

Accrued expenses and other liabilities<\/span><\/p>\n

731,793<\/span><\/p>\n<\/p>\n

740,827<\/span><\/p>\n<\/p>\n

101,940<\/span><\/p>\n<\/p>\n

Income tax payable<\/span><\/p>\n

1,522<\/span><\/p>\n<\/p>\n

1,581<\/span><\/p>\n<\/p>\n

218<\/span><\/p>\n<\/p>\n

Operating lease liabilities, current<\/span><\/p>\n

46,492<\/span><\/p>\n<\/p>\n

35,700<\/span><\/p>\n<\/p>\n

4,912<\/span><\/p>\n<\/p>\n

Short-term bank and other borrowings<\/span><\/p>\n

319,625<\/span><\/p>\n<\/p>\n

363,446<\/span><\/p>\n<\/p>\n

50,012<\/span><\/p>\n<\/p>\n

Long-term bank and other borrowings, current portion<\/span><\/p>\n

722,563<\/span><\/p>\n<\/p>\n

793,760<\/span><\/p>\n<\/p>\n

109,225<\/span><\/p>\n<\/p>\n

Derivative liability<\/span><\/p>\n

163<\/span><\/p>\n<\/p>\n

109,632<\/span><\/p>\n<\/p>\n

15,086<\/span><\/p>\n<\/p>\n

Total current liabilities<\/span><\/p>\n

1,951,394<\/span><\/p>\n<\/p>\n

2,172,280<\/span><\/p>\n<\/p>\n

298,915<\/span><\/p>\n<\/p>\n

\u00a0<\/span><\/p>\n

Non-current liabilities<\/span><\/p>\n

Long-term bank and other borrowings, non-current portion<\/span><\/p>\n

1,994,014<\/span><\/p>\n<\/p>\n

2,211,862<\/span><\/p>\n<\/p>\n

304,362<\/span><\/p>\n<\/p>\n

Deferred tax liabilities<\/span><\/p>\n

99,538<\/span><\/p>\n<\/p>\n

92,807<\/span><\/p>\n<\/p>\n

12,771<\/span><\/p>\n<\/p>\n

Operating lease liabilities, non-current<\/span><\/p>\n

193,007<\/span><\/p>\n<\/p>\n

159,461<\/span><\/p>\n<\/p>\n

21,943<\/span><\/p>\n<\/p>\n

Other long-term liabilities<\/span><\/p>\n

69,003<\/span><\/p>\n<\/p>\n

65,397<\/span><\/p>\n<\/p>\n

9,000<\/span><\/p>\n<\/p>\n

Total non-current liabilities<\/span><\/p>\n

2,355,562<\/span><\/p>\n<\/p>\n

2,529,527<\/span><\/p>\n<\/p>\n

348,076<\/span><\/p>\n<\/p>\n

\u00a0<\/span><\/p>\n

Total liabilities<\/span><\/p>\n

\u00a0<\/p>\n

4,306,956<\/span><\/p>\n<\/p>\n

\u00a0<\/p>\n

4,701,807<\/span><\/p>\n<\/p>\n

\u00a0<\/p>\n

646,991<\/span><\/p>\n<\/p>\n

EQUITY<\/span><\/p>\n

Class A ordinary shares<\/span><\/p>\n

68<\/span><\/p>\n<\/p>\n

68<\/span><\/p>\n<\/p>\n

9<\/span><\/p>\n<\/p>\n

Class B ordinary shares<\/span><\/p>\n

37<\/span><\/p>\n<\/p>\n

37<\/span><\/p>\n<\/p>\n

5<\/span><\/p>\n<\/p>\n

Treasury stock<\/span><\/p>\n

(7)<\/span><\/p>\n<\/p>\n

(7)<\/span><\/p>\n<\/p>\n

(1)<\/span><\/p>\n<\/p>\n

Additional paid-in capital<\/span><\/p>\n

2,007,965<\/span><\/p>\n<\/p>\n

2,169,695<\/span><\/p>\n<\/p>\n

298,560<\/span><\/p>\n<\/p>\n

Accumulated other comprehensive loss<\/span><\/p>\n

(65,419)<\/span><\/p>\n<\/p>\n

(71,694)<\/span><\/p>\n<\/p>\n

(9,865)<\/span><\/p>\n<\/p>\n

Accumulated deficit<\/span><\/p>\n

(4,064,589)<\/span><\/p>\n<\/p>\n

(4,236,847)<\/span><\/p>\n<\/p>\n

(583,010)<\/span><\/p>\n<\/p>\n

Total Concord Medical Services Holdings Limited shareholders’ deficit<\/span><\/p>\n

(2,121,945)<\/span><\/p>\n<\/p>\n

(2,138,748)<\/span><\/p>\n<\/p>\n

(294,302)<\/span><\/p>\n<\/p>\n

Noncontrolling interests<\/span><\/p>\n

3,868,932<\/span><\/p>\n<\/p>\n

4,059,634<\/span><\/p>\n<\/p>\n

558,624<\/span><\/p>\n

Total equity<\/span><\/p>\n

1,746,987<\/span><\/p>\n<\/p>\n

1,920,886<\/span><\/p>\n<\/p>\n

264,322<\/span><\/p>\n

Total liabilities and equity<\/span><\/p>\n

6,053,943<\/span><\/p>\n<\/p>\n

6,622,693<\/span><\/p>\n<\/p>\n

911,313<\/span><\/p>\n<\/p>\n<\/div>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\n

Concord Medical Services Holdings Co., Ltd.<\/span><\/p>\n

Consolidated Profit & Loss<\/span><\/p>\n

(in thousands, except for number of shares and per share data)<\/span><\/p>\n

June 30,
2023<\/span><\/p>\n<\/p>\n

June 30, 2024<\/span><\/p>\n<\/p>\n

RMB<\/span><\/p>\n<\/p>\n

RMB<\/span><\/p>\n<\/p>\n

US$<\/span><\/p>\n<\/p>\n

(Unaudited)<\/span><\/p>\n<\/p>\n

(Unaudited)<\/span><\/p>\n<\/p>\n

(Unaudited)<\/span><\/p>\n

Revenues, net of business tax, value-added tax and related
surcharges<\/span><\/p>\n<\/p>\n

Hospital<\/span><\/p>\n

158,707<\/span><\/p>\n<\/p>\n

137,772<\/span><\/p>\n<\/p>\n

18,958<\/span><\/p>\n

Network<\/span><\/p>\n

125,806<\/span><\/p>\n<\/p>\n

81,038<\/span><\/p>\n<\/p>\n

11,151<\/span><\/p>\n

Total net revenues<\/span><\/p>\n

284,513<\/span><\/p>\n<\/p>\n

218,810<\/span><\/p>\n<\/p>\n

30,109<\/span><\/p>\n

Cost of revenues:<\/span><\/p>\n<\/p>\n

Hospital<\/span><\/p>\n

(204,433)<\/span><\/p>\n<\/p>\n

(173,963)<\/span><\/p>\n<\/p>\n

(23,938)<\/span><\/p>\n

Network<\/span><\/p>\n

(117,503)<\/span><\/p>\n<\/p>\n

(86,443)<\/span><\/p>\n<\/p>\n

(11,895)<\/span><\/p>\n

Total cost of revenues<\/span><\/p>\n

(321,936)<\/span><\/p>\n<\/p>\n

(260,406)<\/span><\/p>\n<\/p>\n

(35,833)<\/span><\/p>\n

Gross loss<\/span><\/p>\n

(37,423)<\/span><\/p>\n<\/p>\n

(41,596)<\/span><\/p>\n<\/p>\n

(5,724)<\/span><\/p>\n

Operating expenses:<\/span><\/p>\n<\/p>\n

Selling expenses<\/span><\/p>\n

(26,362)<\/span><\/p>\n<\/p>\n

(24,975)<\/span><\/p>\n<\/p>\n

(3,437)<\/span><\/p>\n

General and administrative expenses<\/span><\/p>\n

(150,240)<\/span><\/p>\n<\/p>\n

(131,173)<\/span><\/p>\n<\/p>\n

(18,050)<\/span><\/p>\n

Operating loss<\/span><\/p>\n

(214,025)<\/span><\/p>\n<\/p>\n

(197,744)<\/span><\/p>\n<\/p>\n

(27,211)<\/span><\/p>\n

Interest expense<\/span><\/p>\n

(84,374)<\/span><\/p>\n<\/p>\n

(68,668)<\/span><\/p>\n<\/p>\n

(9,449)<\/span><\/p>\n

Foreign exchange loss, net<\/span><\/p>\n

(2,444)<\/span><\/p>\n<\/p>\n

(30,269)<\/span><\/p>\n<\/p>\n

(4,165)<\/span><\/p>\n

Gain on disposal of long-lived equipment<\/span><\/p>\n

62<\/span><\/p>\n<\/p>\n

–<\/span><\/p>\n<\/p>\n

–<\/span><\/p>\n

Interest income<\/span><\/p>\n

5,800<\/span><\/p>\n<\/p>\n

5,990<\/span><\/p>\n<\/p>\n

824<\/span><\/p>\n

Change in fair value of derivative liability<\/span><\/p>\n

–<\/span><\/p>\n<\/p>\n

(108,777)<\/span><\/p>\n<\/p>\n

(14,968)<\/span><\/p>\n

Income from equity method investments<\/span><\/p>\n

10,099<\/span><\/p>\n<\/p>\n

6,070<\/span><\/p>\n<\/p>\n

835<\/span><\/p>\n

Gain on disposal of subsidiaries<\/span><\/p>\n

–<\/span><\/p>\n<\/p>\n

47,997<\/span><\/p>\n<\/p>\n

6,605<\/span><\/p>\n

Other income, net<\/span><\/p>\n

13,623<\/span><\/p>\n<\/p>\n

1,388<\/span><\/p>\n<\/p>\n

191<\/span><\/p>\n

Gain on disposal of equity method investment<\/span><\/p>\n

37,498<\/span><\/p>\n<\/p>\n

–<\/span><\/p>\n<\/p>\n

–<\/span><\/p>\n

Changes in fair value of short-term investments<\/span><\/p>\n

–<\/span><\/p>\n<\/p>\n

6,631<\/span><\/p>\n<\/p>\n

912<\/span><\/p>\n

Loss before income tax<\/span><\/p>\n

(233,761)<\/span><\/p>\n<\/p>\n

(337,382)<\/span><\/p>\n<\/p>\n

(46,426)<\/span><\/p>\n

Income tax expenses<\/span><\/p>\n

23,417<\/span><\/p>\n<\/p>\n

8,674<\/span><\/p>\n<\/p>\n

1,194<\/span><\/p>\n

Net loss<\/span><\/p>\n

(210,344)<\/span><\/p>\n<\/p>\n

(328,708)<\/span><\/p>\n<\/p>\n

(45,232)<\/span><\/p>\n

Net loss attributable to noncontrolling interests<\/span><\/p>\n

(119,359)<\/span><\/p>\n<\/p>\n

(156,450)<\/span><\/p>\n<\/p>\n

(21,528)<\/span><\/p>\n

Net loss attributable to Concord Medical Services Holdings
Limited<\/span><\/p>\n

(90,985)<\/span><\/p>\n<\/p>\n

(172,258)<\/span><\/p>\n<\/p>\n

(23,704)<\/span><\/p>\n

Loss per share for Class A and Class B ordinary shares<\/span><\/p>\n<\/p>\n

Basic<\/span><\/p>\n

(0.69)<\/span><\/p>\n<\/p>\n

(1.31)<\/span><\/p>\n<\/p>\n

(0.18)<\/span><\/p>\n

Diluted<\/span><\/p>\n

(0.69)<\/span><\/p>\n<\/p>\n

(1.31)<\/span><\/p>\n<\/p>\n

(0.18)<\/span><\/p>\n

Weighted average number of class A and class B ordinary shares
outstanding:<\/span><\/p>\n<\/p>\n

Basic<\/span><\/p>\n

131,053,858<\/span><\/p>\n<\/p>\n

131,053,858<\/span><\/p>\n<\/p>\n

131,053,858<\/span><\/p>\n

Diluted<\/span><\/p>\n

131,053,858<\/span><\/p>\n<\/p>\n

131,053,858<\/span><\/p>\n<\/p>\n

131,053,858<\/span><\/p>\n

Other comprehensive loss, net of tax of nil<\/span><\/p>\n<\/p>\n

Foreign currency translation, net of tax of nil<\/span><\/p>\n

(17,371)<\/span><\/p>\n<\/p>\n

(6,273)<\/span><\/p>\n<\/p>\n

(863)<\/span><\/p>\n

Total other comprehensive loss, net of tax<\/span><\/p>\n

(17,371)<\/span><\/p>\n<\/p>\n

(6,273)<\/span><\/p>\n<\/p>\n

(863)<\/span><\/p>\n

Comprehensive loss<\/span><\/p>\n

(227,715)<\/span><\/p>\n<\/p>\n

(334,981)<\/span><\/p>\n<\/p>\n

(46,095)<\/span><\/p>\n

Comprehensive loss attributable to noncontrolling interests<\/span><\/p>\n

(119,359)<\/span><\/p>\n<\/p>\n

(156,450)<\/span><\/p>\n<\/p>\n

(21,528)<\/span><\/p>\n

Comprehensive loss attributable to Concord Medical Services
Holdings Limited’s shareholders<\/span><\/p>\n

(108,356)<\/span><\/p>\n<\/p>\n

(178,531)<\/span><\/p>\n<\/p>\n

(24,567)<\/span><\/p>\n<\/div>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\n

Reconciliations\u00a0of non-GAAP results of operations measures to the
nearest comparable GAAP measures<\/span><\/p>\n

(in\u00a0RMB\u00a0thousands, except per share data unaudited)<\/span><\/p>\n<\/p>\n

For the six months ended<\/span><\/p>\n<\/p>\n

For the six months ended<\/span><\/p>\n

June 30, 2023<\/span><\/p>\n<\/p>\n

June 30, 2024<\/span><\/p>\n

Non-<\/span><\/p>\n<\/p>\n

Non-<\/span><\/p>\n

GAAP<\/span><\/p>\n<\/p>\n

GAAP<\/span><\/p>\n<\/p>\n

GAAP<\/span><\/p>\n<\/p>\n

GAAP<\/span><\/p>\n

Measure<\/span><\/p>\n<\/p>\n

Adjustment<\/span><\/p>\n<\/p>\n

Measure<\/span><\/p>\n<\/p>\n

Measure<\/span><\/p>\n<\/p>\n

Adjustment<\/span><\/p>\n<\/p>\n

Measure<\/span><\/p>\n

Operating loss<\/span><\/p>\n<\/p>\n

(214,025)<\/span><\/p>\n<\/p>\n

–<\/span><\/p>\n<\/p>\n

(214,025)<\/span><\/p>\n<\/p>\n

(197,744)<\/span><\/p>\n<\/p>\n

–<\/span><\/p>\n<\/p>\n

(197,744)<\/span><\/p>\n

Net loss<\/span><\/p>\n<\/p>\n

(210,344)<\/span><\/p>\n<\/p>\n

–<\/span><\/p>\n<\/p>\n

(210,344)<\/span><\/p>\n<\/p>\n

(328,708)<\/span><\/p>\n<\/p>\n

–<\/span><\/p>\n<\/p>\n

(328,708)<\/span><\/p>\n

Basic loss per share for
\u00a0 Class A and<\/span><\/p>\n

Class B ordinary
\u00a0 shares<\/span><\/p>\n<\/p>\n

(0.69)<\/span><\/p>\n<\/p>\n

–<\/span><\/p>\n<\/p>\n

(0.69)<\/span><\/p>\n<\/p>\n

(1.31)<\/span><\/p>\n<\/p>\n

–<\/span><\/p>\n<\/p>\n

(1.31)<\/span><\/p>\n

Diluted loss per share
\u00a0 for Class A and<\/span><\/p>\n

Class B ordinary
\u00a0 shares<\/span><\/p>\n<\/p>\n

(0.69)<\/span><\/p>\n<\/p>\n

–<\/span><\/p>\n<\/p>\n

(0.69)<\/span><\/p>\n<\/p>\n

(1.31)<\/span><\/p>\n<\/p>\n

–<\/span><\/p>\n<\/p>\n

(1.31)<\/span><\/p>\n<\/p>\n<\/div>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\n

Reconciliation from net income to adjusted EBITDA(*) (in\u00a0RMB\u00a0
thousands, unaudited)<\/span><\/p>\n

For the six months ended<\/span><\/p>\n<\/p>\n

For the six months ended<\/span><\/p>\n<\/p>\n

June 30, 2023<\/span><\/p>\n<\/p>\n

June 30, 2024<\/span><\/p>\n

Net loss<\/span><\/p>\n

(210,344)<\/span><\/p>\n<\/p>\n

(328,708)<\/span><\/p>\n

Interest expenses, net<\/span><\/p>\n

78,574<\/span><\/p>\n<\/p>\n

62,678<\/span><\/p>\n

Income tax expenses<\/span><\/p>\n

(23,417)<\/span><\/p>\n<\/p>\n

(8,674)<\/span><\/p>\n

Depreciation and amortization<\/span><\/p>\n

55,537<\/span><\/p>\n<\/p>\n

43,654<\/span><\/p>\n

Share-based compensation<\/span><\/p>\n

–<\/span><\/p>\n<\/p>\n

–<\/span><\/p>\n

Other adjustments<\/span><\/p>\n

(48,739)<\/span><\/p>\n<\/p>\n

83,030<\/span><\/p>\n

Adjusted EBITDA<\/span><\/p>\n

(148,389)<\/span><\/p>\n<\/p>\n

(148,020)<\/span><\/p>\n

EBITDA margin<\/span><\/p>\n

-52\u00a0%<\/span><\/p>\n<\/p>\n

-68\u00a0%<\/span><\/p>\n<\/p>\n

(*) Definition of adjusted EBITDA: Adjusted EBITDA is defined as net loss plus interest expenses, net, income tax expenses,
depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign
exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair
value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment.\u00a0<\/span><\/p>\n<\/div>\n

\u00a0<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-9834","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/9834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9834"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/9834\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}